Novartis signs macrocyclic deal with Unnatural Products for $100M upfront / Endpoints

Kyle LaHucik / endpoints - Novartis will pay $100 million upfront to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines. The move allows the Swiss pharma giant to delve ...

Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA / MedCity

Frank Vinluan / medcitynews - The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FD…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug

18 days / endpoints / ENDPOINTS

Immedica wins accelerated approval for once-rejected rare disease drug

20 days / endpoints / Zachary Brennan

FDA proposes new system for approving customized drugs and therapies for rare diseases

20 days / medicalxpress

FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher

27 days / endpoints / Max Gelman

Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA

28 days / medcitynews / Frank Vinluan

Saturday, February 21, 2026, 6:22 am / permalink 19516 / 5 stories in 23 days

Walgreens to lay off hundreds of employees / Healthcare Dive

Dani James / healthcaredive - The drugstore retailer said it was simplifying its organization to speed up decision-making in a move impacting at least 600 workers.

#healthcare #pharmaceuticals #mergersandacquisitions

Walgreens to lay off hundreds of employees

24 days / healthcaredive / Dani James

Walgreens to cut 628 jobs

25 days / beckershospitalreview / Ella Jeffries

Saturday, February 21, 2026, 12:23 am / permalink 19503 / 2 stories in 23 days

'Universal' nasal-spray vaccine protects against viruses, bacteria and allergens in mice / LiveScience

livescience - In an early animal test, a new nasal-spray vaccine has shown promise against a variety of germs and a common allergen, scientists report.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #vaccinesafety

'Universal' nasal-spray vaccine protects against viruses, bacteria and allergens in mice

24 days / livescience

Closing in on a universal vaccine: Nasal spray protects mice from respiratory viruses, bacteria and allergens

25 days / medicalxpress

Single vaccine could protect against all coughs, colds and flus, researchers say

25 days / bbc

Friday, February 20, 2026, 5:22 pm / permalink 19489 / 3 stories in 24 days

Your Cat May Share the Same Cancer Genes as You, and Offer Clues for Treatment / Discover

discovermagazine - Learn how cats and humans can share key cancer mutations — and why those similarities could guide future treatment research.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #oncology

Cats may hold clues for human cancer treatment

25 days / bbc

Your Cat May Share the Same Cancer Genes as You, and Offer Clues for Treatment

25 days / discovermagazine

Household cat could hold the key to understanding breast cancer

25 days / medicalxpress

Thursday, February 19, 2026, 9:23 pm / permalink 19449 / 3 stories in 24 days

Immune cells from pediatricians help uncover an antibody cocktail against RSV and hMPV / Medical Express

medicalxpress - Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for protection against two common viruses. The proposed preventative treatment consists of antibodies identified in pediatricians who have…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #infanthealth

Immune cells from pediatricians help uncover an antibody cocktail against RSV and hMPV

25 days / medicalxpress

Paediatricians’ blood used to make new treatments for RSV and colds

26 days / newscientist

Antibody cocktails based on the occupationally acquired immunity of pediatricians neutralize and confer protection against RSV and hMPV

26 days / science / Hui Zhai, Wenxiang Yu, Jinyue Wang, Jie Deng, Siyu Lei, Teng Zhou, Yixin Li, Kaijun Xu, Mengyang Ma,

Thursday, February 19, 2026, 12:24 pm / permalink 19427 / 3 stories in 25 days

FDA formalizes one pivotal trial policy via NEJM perspective / Endpoints

Zachary Brennan / endpoints - Top FDA officials said that a single pivotal trial requirement will be the “new default standard” for drug approvals, a move that goes beyond the agency’s prior discretion around not requiring two trials. In a ...

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda

FDA formalizes one pivotal trial policy via NEJM perspective

25 days / endpoints / Zachary Brennan

FDA to drop 2-study requirement, expand OTC access

25 days / beckershospitalreview / Ella Jeffries

FDA will drop two-study requirement for new drug approvals, aiming to speed access

25 days / medicalxpress

Thursday, February 19, 2026, 11:24 am / permalink 19422 / 3 stories in 25 days

F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine / NYT

Christina Jewett and Rebecca Robbins / nytimes - Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #vaccinesafety

Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more

23 days / endpoints / Max Gelman

FDA's abrupt flip-flop on Moderna's mRNA flu shot highlights growing risks to drug-makers of investing in vaccines

25 days / medicalxpress

What the Health? From KFF Health News: Turnarounds and Shake-Ups

25 days / kffhealthnews

Study shows low vaccination rates among expectant mothers in Norway against COVID-19, influenza

25 days / medicalxpress

FDA reverses course; agrees to review Moderna flu vaccine

26 days / beckershospitalreview / Erica Cerutti

Reversal on Moderna's flu application follows atypical path through FDA

26 days / endpoints / Zachary Brennan

Moderna says the FDA will consider its new flu shot after resolving a public dispute

26 days / abcnews

In reversal, US agrees to review new Moderna flu shot

26 days / medicalxpress

FDA reverses course on Moderna’s flu vaccine

26 days / healthcaredive / Delilah Alvarado

F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine

26 days / nytimes / Christina Jewett and Rebecca Robbins

FDA reverses course, will review Moderna’s flu vaccine

26 days / endpoints / Max Bayer

Wednesday, February 18, 2026, 9:23 am / permalink 19353 / 11 stories in 26 days

Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test / MedCity

Frank Vinluan / medcitynews - In the first of two Phase 3 tests, Ocular Therapeutix’s Axpaxli met the main goal of helping maintain vision in patients with the wet form of age-related macular degeneration. The Ocular drug was compared to Eylea, a blockbuster wet AMD drug marketed by R…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test

27 days / medcitynews / Frank Vinluan

Ocular Therapeutix’s Axpaxli could become first choice in wet AMD after showing superiority over Eylea

27 days / endpoints / Elizabeth Cairns

Bruce Haffty Joins ACR as the Chief Medical Officer for Radiation Oncology Research

29 days / oncodaily

Tuesday, February 17, 2026, 9:22 pm / permalink 19334 / 3 stories in 26 days

Lilly appeals retatrutide classification ruling in case that could impact compounders / Endpoints

Alexis Kramer / endpoints - Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it. On Thursday, Lilly filed a notice ...

#obesity #healthcare #pharmaceuticals #elililly #weightloss #publichealth #drugdevelopment #fda #digitalhealth

Eli Lilly tests GLP-1 psoriasis combo in phase 3 trial

24 days / beckershospitalreview / Ella Jeffries

Video: Using combined therapy to treat obesity

25 days / medicalxpress

What's next for GLP-1s?

25 days / medicalxpress

Weight-loss drug 'support supplements': Do they address nutrient deficiencies, or are they just another fad?

27 days / medicalxpress

Weight-loss wonder pills prompt scrutiny of their key ingredient

27 days / medicalxpress

Taking the next shot: GLP-1 research and the new era of weight loss

27 days / medicalxpress

Overweight, obesity remained highly prevalent in US youths in 2024

27 days / medicalxpress

Inside Health

27 days / bbc

Bariatric surgery programs face upheaval amid growing GLP-1 use for weight loss

28 days / medicalxpress

Drugs Behind Ozempic and Wegovy Are Being Repurposed — Here Are 5 Others

28 days / discovermagazine

Will Ozempic-style patches help you lose weight? Two experts explain

29 days / medicalxpress

Obesity rates are rising, despite GLP-1s. What does it mean?

29 days / medicalxpress

White-label telehealth provider, pharmacy sued over 'snake oil' compounded oral GLP-1

4 wks / fiercehealthcare

Lilly appeals retatrutide classification ruling in case that could impact compounders

4 wks / endpoints / Alexis Kramer

Lilly stockpiles $1.5B worth of weight loss pill ahead of US approval

4 wks / endpoints / Anna Brown

Saturday, February 14, 2026, 12:21 pm / permalink 19191 / 15 stories in 4 wks

HPV cancer vaccine slows tumor growth and extends survival in preclinical model / Medical Express

medicalxpress - Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure. After proving this concept across multiple studies, the…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

This reengineered HPV vaccine trains T cells to hunt down cancer

26 days / sciencedaily

Cancer virus imaging helps uncover potential therapeutic targets

28 days / medicalxpress

Dual brakes on T-cells: New targets found to boost immunity in chronic infections

28 days / medicalxpress

Cancer vaccine shows promise against HPV-related throat tumors in early study

4 wks / livescience

HPV cancer vaccine slows tumor growth and extends survival in preclinical model

4 wks / medicalxpress

Saturday, February 14, 2026, 5:21 am / permalink 19182 / 5 stories in 4 wks

Studies test whether gene-editing can fix high cholesterol. For now, take your medicine / Medical Express

medicalxpress - Scientists are testing an entirely new way to fight heart disease: a gene-editing treatment that might offer a one-time fix for high cholesterol.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Nanoparticle-based gene editing could expand treatment options for cystic fibrosis

27 days / medicalxpress

Massive study finds most statin side effects aren’t caused by the drugs

29 days / sciencedaily

Studies test whether gene-editing can fix high cholesterol. For now, take your medicine

4 wks / go

Studies test whether gene-editing can fix high cholesterol. For now, take your medicine

4 wks / medicalxpress

Saturday, February 14, 2026, 3:21 am / permalink 19179 / 4 stories in 4 wks

Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B / MedCity

Frank Vinluan / medcitynews - Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by …

#healthcare #pharmaceuticals #elililly #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Al-Ola Abdallah: Discussing Updates of CAR-T in Malignant Hematology with Nausheen Ahmed

26 days / oncodaily

J&J pours $1B into new cell therapy site in Pennsylvania

26 days / endpoints / Nicole DeFeudis

Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront

26 days / endpoints / Elizabeth Cairns

One stem cell generates 14 million tumor-killing NK cells in major cancer breakthrough

26 days / sciencedaily

Caroline Pothet: The 2026 Workplan of the Committee For Advanced Therapies is Available

27 days / oncodaily

Eddie Cliff: Why CAR T Infusion Timing Doesn’t Change Outcomes in LBCL

27 days / oncodaily

Optimizing CAR T-cell therapy to tackle solid tumors

28 days / medicalxpress

Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B

5 wks / medcitynews / Frank Vinluan

Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition

5 wks / endpoints / Kyle LaHucik

Saturday, February 14, 2026, 3:21 am / permalink 19178 / 9 stories in 4 wks

Sanofi's Paul Hudson out, with Belén Garijo to step in as new CEO / Endpoints

Reynald Castañeda / endpoints - Paul Hudson is stepping down from his post as CEO of Sanofi, and his last day will be Feb. 17. The French drugmaker's board decided not to renew Hudson's mandate on ...

#healthcare #pharmaceuticals #biotech #drugdevelopment

Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more

4 wks / endpoints / Nicole DeFeudis

Sanofi's Paul Hudson out, with Belén Garijo to step in as new CEO

4 wks / endpoints / Reynald Castañeda

Medical neglect contributed to mother's death, inquest finds

4 wks / bbc

Saturday, February 14, 2026, 3:20 am / permalink 19177 / 3 stories in 4 wks

Ama launches independent vaccine review after CDC criticism / Medical Express

medicalxpress - Two major medical groups will begin reviewing vaccine safety and effectiveness after major changes at the U.S. Centers for Disease Control and Prevention (CDC) have raised alarms among experts.

#healthcare #pharmaceuticals #publichealth #governmentpolicy #cdc #vaccinesafety

Vaccine denial sets Americans up for more chronic illness

29 days / livescience

Large study finds no link between mRNA COVID vaccine in pregnancy and autism

29 days / sciencedaily

Ama launches independent vaccine review after CDC criticism

4 wks / medicalxpress

AMA partners with research group to review vaccine safety, effectiveness

4 wks / beckershospitalreview / Mackenzie Bean

Saturday, February 14, 2026, 12:22 am / permalink 19173 / 4 stories in 4 wks

BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing / MedCity

Frank Vinluan / medcitynews - Infigratinib achieved statistically significant improvement in growth rate and body composition in a Phase 3 clinical trial that tested the BridgeBio Pharma drug in achondroplasia, the most common form of dwarfism. Regulatory submissions are planned for l…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing

4 wks / medcitynews / Frank Vinluan

BridgeBio's dwarfism drug succeeds in Phase 3, adding to recent late-stage wins

4 wks / endpoints / Max Gelman

Saturday, February 14, 2026, 12:22 am / permalink 19171 / 2 stories in 4 wks

AbbVie sues over selection of Botox for IRA negotiations / Endpoints

Nicole DeFeudis / endpoints - AbbVie is suing CMS for picking Botox for the third round of Medicare negotiations, making it the first drugmaker to challenge the upcoming cycle in court. In a lawsuit filed Wednesday in Washington, DC, AbbVie ...

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy

AbbVie sues over selection of Botox for IRA negotiations

4 wks / endpoints / Nicole DeFeudis

AbbVie sues HHS over Medicare drug price controls

4 wks / beckershospitalreview / Ella Jeffries

Saturday, February 14, 2026, 12:22 am / permalink 19169 / 2 stories in 4 wks

FDA refuses to review Moderna flu vaccine / Beckers

Ella Jeffries / beckershospitalreview - Moderna has received a refusal-to-file letter from the FDA’s Center for Biologics Evaluation and Research for its biologics license application for mRNA-1010, its investigational seasonal influenza vaccine. The letter, signed by Vinayak Prasad, MD, chief …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda

Moderna's flu shot dilemma muddies 2028 break-even guidance

4 wks / endpoints / Max Bayer

The Old System Failed Patients. Change Must Go Further and Faster – Garo Armen

Tag Directory / PHARMACEUTICALS showing 41–60 of 120

PHARMACEUTICALS Heatmap

More Top Stories...